General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 210006, Nanjing, Jiangsu, China.
Medical College, Southeast University, 210009, Nanjing, Jiangsu, China.
Cell Death Dis. 2019 Feb 12;10(2):131. doi: 10.1038/s41419-018-1188-3.
MicroRNAs (miRNAs) are important class of functional regulators involved in human cancers development, including colorectal cancer (CRC). Exploring aberrantly expressed miRNAs may provide us with new insights into the initiation and development of CRC by functioning as oncogenes or tumor suppressors. The aim of our study is to discover the expression pattern of miR-1249 in CRC and investigate its clinical significance as well as biological role in CRC progression. In our study, we found that miR-1249 was markedly downregulated in CRC tissues and cell lines, and negatively related to pN stage, pM stage, TNM stage, and overall survival (OS). Moreover, we demonstrated that miR-1249 was a direct transcriptional target of P53 and revealed that P53-induced miR-1249 inhibited tumor growth, metastasis and angiogenesis in vitro and vivo. Additionally, we verified that miR-1249 suppressed CRC proliferation and angiogenesis by targeting VEGFA as well as inhibited CRC metastasis by targeting both VEGFA and HMGA2. Further studying showed that miR-1249 suppressed CRC cell proliferation, migration, invasion, and angiogenesis via VEGFA-mediated Akt/mTOR pathway as well as inhibited EMT process of CRC cells by targeting both VEGFA and HMGA2. Our study indicated that P53-induced miR-1249 may suppress CRC growth, metastasis and angiogenesis by targeting VEGFA and HMGA2, as well as regulate Akt/mTOR pathway and EMT process in the initiation and development of CRC. miR-1249 might be a novel the therapeutic candidate target in CRC treatment.
微小 RNA(miRNAs)是参与人类癌症发展的重要功能调节剂,包括结直肠癌(CRC)。探索异常表达的 miRNAs 可能通过作为癌基因或肿瘤抑制因子为 CRC 的起始和发展提供新的见解。我们的研究旨在发现 miR-1249 在 CRC 中的表达模式,并研究其在 CRC 进展中的临床意义和生物学作用。在我们的研究中,我们发现 miR-1249 在 CRC 组织和细胞系中明显下调,与 pN 分期、pM 分期、TNM 分期和总生存期(OS)呈负相关。此外,我们证明 miR-1249 是 P53 的直接转录靶标,并揭示了 P53 诱导的 miR-1249 抑制了体外和体内肿瘤的生长、转移和血管生成。此外,我们验证了 miR-1249 通过靶向 VEGFA 抑制 CRC 增殖和血管生成,通过靶向 VEGFA 和 HMGA2 抑制 CRC 转移。进一步研究表明,miR-1249 通过 VEGFA 介导的 Akt/mTOR 通路抑制 CRC 细胞增殖、迁移、侵袭和血管生成,并通过靶向 VEGFA 和 HMGA2 抑制 CRC 细胞 EMT 过程。我们的研究表明,P53 诱导的 miR-1249 可能通过靶向 VEGFA 和 HMGA2 抑制 CRC 的生长、转移和血管生成,并调节 Akt/mTOR 通路和 EMT 过程在 CRC 的发生和发展中。miR-1249 可能是 CRC 治疗的一种新的治疗候选靶点。